Points to Note about Analog Abc Research Chemical

You may also like...

2 Responses

  1. tryptamine says:

    It’s no secret that pharmaceutical manufacturers have one intention in business — to make money.

    The pharmaceutical industry rakes in around $300 billion annually, a price tag that is expected to increase by another billion within only three years’ time, according to the World Health Organization. Additionally, six of the 10 largest drug-making companies in the world are right here in America.

    While it is certainly possible to profit a great deal from the rampant illnesses of undeveloped nations combined with the high rate of diagnoses like cancer in Western civilization, that isn’t how big pharma companies are making their billions. Drugs are costly, and for many, impossible to obtain because of the heavy price tag. In 2012, 12 new drugs were approved by the Food and Drug Administration and of them, 11 would cost more than $100,000 to treat one person for one year, per AlterNet.

  2. Chemical Genetic Analysis and Functional Characterization of Staphylococcal Wall Teichoic Acid 2-Epimerases Reveals Unconventional Antibiotic Drug Targets says:

    Here we describe a chemical biology strategy performed in Staphylococcus aureus and Staphylococcus epidermidis to identify MnaA, a 2-epimerase that we demonstrate interconverts UDP-GlcNAc and UDP-ManNAc to modulate substrate levels of TarO and TarA wall teichoic acid (WTA) biosynthesis enzymes. Genetic inactivation of mnaA results in complete loss of WTA and dramatic in vitro β-lactam hypersensitivity in methicillin-resistant S. aureus (MRSA) and S. epidermidis (MRSE). Likewise, the β-lactam antibiotic imipenem exhibits restored bactericidal activity against mnaA mutants in vitro and concomitant efficacy against 2-epimerase defective strains in a mouse thigh model of MRSA and MRSE infection. Interestingly, whereas MnaA serves as the sole 2-epimerase required for WTA biosynthesis in S. epidermidis, MnaA and Cap5P provide compensatory WTA functional roles in S. aureus. We also demonstrate that MnaA and other enzymes of WTA biosynthesis are required for biofilm formation in MRSA and MRSE. We further determine the 1.9Å crystal structure of S. aureus MnaA and identify critical residues for enzymatic dimerization, stability, and substrate binding. Finally, the natural product antibiotic tunicamycin is shown to physically bind MnaA and Cap5P and inhibit 2-epimerase activity, demonstrating that it inhibits a previously unanticipated step in WTA biosynthesis. In summary, MnaA serves as a new Staphylococcal antibiotic target with cognate inhibitors predicted to possess dual therapeutic benefit: as combination agents to restore β-lactam efficacy against MRSA and MRSE and as non-bioactive prophylactic agents to prevent Staphylococcal biofilm formation.

Leave a Reply

Your email address will not be published. Required fields are marked *